• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Transport of cosalane-a highly lipophilic novel anti-HIV agent-across caco-2 cell monolayers.

作者信息

Pal D, Udata C, Mitra A K

机构信息

Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, 5005 Rockhill Road, Kansas City, Missouri 64110, USA.

出版信息

J Pharm Sci. 2000 Jun;89(6):826-33. doi: 10.1002/(SICI)1520-6017(200006)89:6<826::AID-JPS15>3.0.CO;2-4.

DOI:10.1002/(SICI)1520-6017(200006)89:6<826::AID-JPS15>3.0.CO;2-4
PMID:10824142
Abstract

Cosalane is a potent inhibitor of HIV replication with activity against a broad range of viral targets. However, the oral bioavailability of this highly lipophilic compound is extremely poor (<1%). Also, cosalane accumulates in high concentration in the liver after intravenous administration, with clear resistance to hepatic metabolism. In the present study, the transcellular permeability of cosalane was examined using Transwell(R) filter as well as plastic-grown confluent Caco-2 cell monolayers. A cell-culture-based biophysical model was adopted to understand the interactions of protein binding, membrane partitioning, and aqueous solubility of cosalane in limiting transcellular flux of cosalane across Caco-2 cell monolayers. The transcellular permeability (P(app)) of cosalane was extremely low (4.494 x 10(-8) cm/s) and the effect of p-glycoprotein on the efflux of cosalane was negligible. A characteristic disparity exists between the kinetics of cosalane uptake from apical (AP) donor solution and efflux into basolateral (BL) receiver side. The AP uptake of cosalane was rapid, exhibiting exponential kinetics, and reached equilibrium within 60 min, whereas the concomitant appearance of the compound into the BL receiver side was slow but linear over time. Furthermore, the uptake of cosalane was significantly reduced in the presence of bovine serum albumin (BSA). In unidirectional efflux studies, AP efflux of cosalane was limited in the absence of BSA. Also, no detectable metabolites were found in Caco-2 cell incubations. In conclusion, the present study demonstrates that diffusion of cosalane across Caco-2 cell monolayers is extremely limited and kinetically regulated essentially by the equilibrium between protein-bound and free drug partitioning into cell membrane.

摘要

相似文献

1
Transport of cosalane-a highly lipophilic novel anti-HIV agent-across caco-2 cell monolayers.
J Pharm Sci. 2000 Jun;89(6):826-33. doi: 10.1002/(SICI)1520-6017(200006)89:6<826::AID-JPS15>3.0.CO;2-4.
2
Enhanced transport of a novel anti-HIV agent--cosalane and its congeners across human intestinal epithelial (Caco-2) cell monolayers.新型抗HIV药物——科萨烷及其同系物在人肠上皮(Caco-2)细胞单层中的转运增强。
Int J Pharm. 2003 Jan 2;250(1):157-68. doi: 10.1016/s0378-5173(02)00523-9.
3
Disposition of cosalane, a novel anti-HIV agent, in isolated perfused rat livers.新型抗HIV药物科索烷在离体灌注大鼠肝脏中的处置情况。
Drug Metab Dispos. 1999 Aug;27(8):947-50.
4
Pharmacokinetics, biliary excretion, and tissue distribution of novel anti-HIV agents, cosalane and dihydrocosalane, in Sprague-Dawley rats.新型抗HIV药物科萨烷和二氢科萨烷在Sprague-Dawley大鼠体内的药代动力学、胆汁排泄及组织分布
Drug Metab Dispos. 2000 Apr;28(4):403-8.
5
Use of a biophysical-kinetic model to understand the roles of protein binding and membrane partitioning on passive diffusion of highly lipophilic molecules across cellular barriers.
J Drug Target. 1993;1(4):269-86. doi: 10.3109/10611869308996085.
6
Binding of cosalane--a novel highly lipophilic anti-HIV agent--to albumin and glycoprotein.新型高亲脂性抗HIV药物科萨烷与白蛋白和糖蛋白的结合
J Pharm Sci. 2001 May;90(5):659-66. doi: 10.1002/1520-6017(200105)90:5<659::aid-jps1022>3.0.co;2-8.
7
Intestinal absorption and biodistribution of cosalane and its amino acid conjugates: novel anti-HIV agents.科萨烷及其氨基酸缀合物的肠道吸收和生物分布:新型抗HIV药物。
Int J Pharm. 2002 Jan 14;231(2):197-211. doi: 10.1016/s0378-5173(01)00884-5.
8
Transport of a novel anti-cancer agent, fenretinide across Caco-2 monolayers.
Invest New Drugs. 2007 Jun;25(3):197-203. doi: 10.1007/s10637-006-9026-3. Epub 2006 Dec 5.
9
[Absorption of coptisine chloride and berberrubine across human intestinal epithelial by using human Caco-2 cell monolayers].[利用人Caco-2细胞单层研究盐酸黄连碱和小檗红碱在人肠道上皮细胞中的吸收]
Zhongguo Zhong Yao Za Zhi. 2007 Dec;32(23):2523-7.
10
Stereoselective transport and uptake of propranolol across human intestinal Caco-2 cell monolayers.立体选择性转运和摄取普罗帕酮穿过人肠 Caco-2 细胞单层。
Chirality. 2010 Mar;22(3):361-8. doi: 10.1002/chir.20753.

引用本文的文献

1
In Vitro Studies to Evaluate the Intestinal Permeation of an Ursodeoxycholic Acid-Conjugated Oligonucleotide for Duchenne Muscular Dystrophy Treatment.评估用于杜氏肌营养不良症治疗的熊去氧胆酸共轭寡核苷酸肠道渗透性的体外研究
Pharmaceutics. 2024 Aug 1;16(8):1023. doi: 10.3390/pharmaceutics16081023.
2
Geraniol Pharmacokinetics, Bioavailability and Its Multiple Effects on the Liver Antioxidant and Xenobiotic-Metabolizing Enzymes.香叶醇的药代动力学、生物利用度及其对肝脏抗氧化酶和外源性物质代谢酶的多重影响。
Front Pharmacol. 2018 Jan 25;9:18. doi: 10.3389/fphar.2018.00018. eCollection 2018.
3
Formulation and evaluation of biodegradable nanoparticles for the oral delivery of fenretinide.
用于口服阿维A酯的可生物降解纳米颗粒的制备与评价。
Eur J Pharm Sci. 2015 Aug 30;76:1-9. doi: 10.1016/j.ejps.2015.04.024. Epub 2015 Apr 28.
4
Effect of water soluble vitamins on Zn transport of Caco-2 cells and their implications under oxidative stress conditions.水溶性维生素对 Caco-2 细胞中 Zn 转运的影响及其在氧化应激条件下的意义。
Eur J Nutr. 2010 Feb;49(1):53-61. doi: 10.1007/s00394-009-0048-4. Epub 2009 Aug 13.
5
Transport of a novel anti-cancer agent, fenretinide across Caco-2 monolayers.
Invest New Drugs. 2007 Jun;25(3):197-203. doi: 10.1007/s10637-006-9026-3. Epub 2006 Dec 5.
6
Characterization of mefenamic acid-guaiacol ester: stability and transport across Caco-2 cell monolayers.
Pharm Res. 2002 Jul;19(7):1013-8. doi: 10.1023/a:1016470523923.